203 related articles for article (PubMed ID: 34702772)
1. Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma.
Cao Y; Haring CT; Brummel C; Bhambhani C; Aryal M; Lee C; Heft Neal M; Bhangale A; Gu W; Casper K; Malloy K; Sun Y; Shuman A; Prince ME; Spector ME; Chinn S; Shah J; Schonewolf C; McHugh JB; Mills RE; Tewari M; Worden FP; Swiecicki PL; Mierzwa M; Brenner JC
Clin Cancer Res; 2022 Jan; 28(2):350-359. PubMed ID: 34702772
[TBL] [Abstract][Full Text] [Related]
2. CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Rosen BS; Wilkie JR; Sun Y; Ibrahim M; Casper KA; Miller JE; Chotchutipan T; Stucken CL; Bradford C; Prince MEP; Rosko AJ; Malloy KM; McLean SA; Chinn SB; Shuman AG; Spector ME; Swiecicki PL; Worden FP; Shah JL; Schonewolf CA; Chapman CH; Eisbruch A; Mierzwa ML
Radiother Oncol; 2021 Feb; 155():174-181. PubMed ID: 33069764
[TBL] [Abstract][Full Text] [Related]
3. HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.
Veyer D; Wack M; Mandavit M; Garrigou S; Hans S; Bonfils P; Tartour E; Bélec L; Wang-Renault SF; Laurent-Puig P; Mirghani H; Rance B; Taly V; Badoual C; Péré H
Int J Cancer; 2020 Aug; 147(4):1222-1227. PubMed ID: 31756275
[TBL] [Abstract][Full Text] [Related]
4. The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
Haring CT; Dermody SM; Yalamanchi P; Kang SY; Old MO; Chad Brenner J; Spector ME; Rocco JW
Oral Oncol; 2022 Mar; 126():105776. PubMed ID: 35183912
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma.
Alluri KC; Tahari AK; Wahl RL; Koch W; Chung CH; Subramaniam RM
AJR Am J Roentgenol; 2014 Oct; 203(4):897-903. PubMed ID: 25247958
[TBL] [Abstract][Full Text] [Related]
6. Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.
O'Boyle CJ; Siravegna G; Varmeh S; Queenan N; Michel A; Pang KCS; Stein J; Thierauf JC; Sadow PM; Faquin WC; Wang W; Deschler DG; Emerick KS; Varvares MA; Park JC; Clark JR; Chan AW; Busse PM; Corcoran RB; Wirth LJ; Lin DT; Iafrate AJ; Richmon JD; Faden DL
Cancer; 2022 Jun; 128(11):2193-2204. PubMed ID: 35139236
[TBL] [Abstract][Full Text] [Related]
7. Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
Schouten CS; Hakim S; Boellaard R; Bloemena E; Doornaert PA; Witte BI; Braakhuis BJ; Brakenhoff RH; Leemans CR; Hoekstra OS; de Bree R
Head Neck; 2016 Apr; 38(4):529-35. PubMed ID: 25352335
[TBL] [Abstract][Full Text] [Related]
8. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
9. Volumetric
Chotchutipan T; Rosen BS; Hawkins PG; Lee JY; Saripalli AL; Thakkar D; Eisbruch A; El Naqa I; Mierzwa ML
Head Neck; 2019 Feb; 41(2):366-373. PubMed ID: 30548704
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI, diffusion-weighted MRI and
Ng SH; Liao CT; Lin CY; Chan SC; Lin YC; Yen TC; Chang JT; Ko SF; Fan KH; Wang HM; Yang LY; Wang JJ
Eur Radiol; 2016 Nov; 26(11):4162-4172. PubMed ID: 26911889
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor α as a predictive biomarker for survival in human papillomavirus-positive oropharyngeal squamous cell carcinoma.
Kwon S; Ahn SH; Jeong WJ; Jung YH; Bae YJ; Paik JH; Chung JH; Kim H
J Transl Med; 2020 Jun; 18(1):240. PubMed ID: 32546279
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of pretreatment 18F-fluorodeoxyglucose positron emission tomography/CT volume-based parameters in patients with oropharyngeal squamous cell carcinoma with known p16 and p53 status.
Kikuchi M; Koyasu S; Shinohara S; Usami Y; Imai Y; Hino M; Itoh K; Tona R; Kanazawa Y; Kishimoto I; Harada H; Naito Y
Head Neck; 2015 Oct; 37(10):1524-31. PubMed ID: 24890445
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment PET/MRI based FDG and DWI imaging parameters for predicting HPV status and tumor response to chemoradiotherapy in primary oropharyngeal squamous cell carcinoma (OPSCC).
Freihat O; Tóth Z; Pintér T; Kedves A; Sipos D; Cselik Z; Lippai N; Repa I; Kovács Á
Oral Oncol; 2021 May; 116():105239. PubMed ID: 33640578
[TBL] [Abstract][Full Text] [Related]
14. Mid-treatment Fluorodeoxyglucose Positron Emission Tomography in Human Papillomavirus-related Oropharyngeal Squamous Cell Carcinoma Treated with Primary Radiotherapy: Nodal Metabolic Response Rate can Predict Treatment Outcomes.
Lin P; Min M; Lai K; Lee M; Holloway L; Xuan W; Bray V; Fowler A; Lee CS; Yong J
Clin Oncol (R Coll Radiol); 2021 Dec; 33(12):e586-e598. PubMed ID: 34373179
[TBL] [Abstract][Full Text] [Related]
15. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer.
Chera BS; Kumar S; Beaty BT; Marron D; Jefferys S; Green R; Goldman EC; Amdur R; Sheets N; Dagan R; Hayes DN; Weiss J; Grilley-Olson JE; Zanation A; Hackman T; Blumberg JM; Patel S; Weissler M; Tan XM; Parker JS; Mendenhall W; Gupta GP
Clin Cancer Res; 2019 Aug; 25(15):4682-4690. PubMed ID: 31088830
[TBL] [Abstract][Full Text] [Related]
16. The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study.
Verduijn GM; Capala ME; Sijtsema ND; Lauwers I; Hernandez Tamames JA; Heemsbergen WD; Sewnaik A; Hardillo JA; Mast H; van Norden Y; Jansen MPHM; van der Lugt A; van Gent DC; Hoogeman MS; Mostert B; Petit SF
BMJ Open; 2022 May; 12(5):e059345. PubMed ID: 35584883
[TBL] [Abstract][Full Text] [Related]
17. Pre-CCRT 18-fluorodeoxyglucose PET-CT improves survival in patients with advanced stages p16-negative oropharyngeal squamous cell carcinoma via accurate radiation treatment planning.
Chen TM; Chen WM; Chen M; Shia BC; Wu SY
J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):14. PubMed ID: 36782296
[TBL] [Abstract][Full Text] [Related]
18. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.
Tang C; Murphy JD; Khong B; La TH; Kong C; Fischbein NJ; Colevas AD; Iagaru AH; Graves EE; Loo BW; Le QT
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1514-20. PubMed ID: 22270174
[TBL] [Abstract][Full Text] [Related]
19. Assessing plasma circulating tumor human papillomavirus (HPV) DNA in determining treatment response in HPV-associated oropharyngeal cancer.
Zarrabi KK; Galloway TJ; Flieder DB; Kumar SS; Judd J; Bauman JR
Head Neck; 2022 Aug; 44(8):E25-E30. PubMed ID: 35546490
[TBL] [Abstract][Full Text] [Related]
20. Intravoxel incoherent motion imaging kinetics during chemoradiotherapy for human papillomavirus-associated squamous cell carcinoma of the oropharynx: preliminary results from a prospective pilot study.
Ding Y; Hazle JD; Mohamed AS; Frank SJ; Hobbs BP; Colen RR; Gunn GB; Wang J; Kalpathy-Cramer J; Garden AS; Lai SY; Rosenthal DI; Fuller CD
NMR Biomed; 2015 Dec; 28(12):1645-54. PubMed ID: 26451969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
